AbbVie Presents New Efficacy Data on Upadacitinib in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021 Pharmaceutical Investing
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® Among Patients with Rheumatoid Arthritis Pharmaceutical Investing
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States Pharmaceutical Investing
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HMLP, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc. Life Science Investing
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO 2021 Annual Meeting Pharmaceutical Investing
Neoadjuvant Opdivo Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial Pharmaceutical Investing
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021 Pharmaceutical Investing
BMY, HEPS, HMLP INVESTOR ALERT BY CLAIMSFILER: Pending Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab in Psoriatic Arthritis at ACR Convergence 2021 Pharmaceutical Investing
